Latest News - Headache & Pain

Friday, September 28, 2018

FDA Approves Galcanezumab for Prevention of Migraine

The Food and Drug Administration (FDA) has approved galcanezumab-glnm (Emgality; Lilly, Indianapolis, IN) for the prevention of migraine in adults. Galcanezumab is available as a self-administered sub…

Read the full story

Monday, September 17, 2018

Fremanezumab-vfrm Approved for Prevention of Migraine

The Food and Drug Administration (FDA) has approved fremanezumab-vfrm (Ajovy; Teva Pharmaceutical Industries, Jerusalem, Israel) for prevention of migraine in adults. Fremanezumab is administered…

Read the full story

Wednesday, September 12, 2018

New Investigational Intranasal CGRP-Antagonist for Treatment of Migraine

An investigational drug application has been filed with the Food and Drug Administration (FDA) for BHV-3500 (Biohaven, New Haven, CT). This new compound is the first intranasal (IN) formulation of a s…

Read the full story

Thursday, September 06, 2018

Phase 3 Results for Rimegepant for Treatment of Migraine Being Presented

Data from 2 phase 3 pivotal trials of rimegepant (Biohaven, New Haven, CT) for treatment of patients with migraine will be presented at the 17th Biennial Migraine Trust International Symposium (MTIS) …

Read the full story

Wednesday, September 05, 2018

Lower Extremity Radicular Pain Relieved With Tetrahydrocannabinol

In a small (n = 17 men), double-blind, placebo-controlled study using a counterbalanced within-subjects design, treatment of patients with chronic neuropathic pain with delta-9-tetrahydrocannibin…

Read the full story

Tuesday, August 28, 2018

NIH Announces Launch of Studies to Understand Acute to Chronic Pain Transition

The National Institutes of Health (NIH) has launched a new program to study how acute pain transitions into chronic pain and to identify biologic characteristics underlying this transition and making …

Read the full story

Thursday, August 16, 2018

Intrathecal Baclofen More Effective Than Oral Medication for Treating Pain in Patients With Poststroke Spasticity

Results from the SISTERS trial (NCT01032239) show that intrathecal administration (ITB Therapy; Medtronic, Dublin, Ireland) of baclofen (Lioresal Intrathecal; Saol Therapeutics, Roswell, GA) is a more…

Read the full story

Monday, July 30, 2018

Breaching the Blood-Brain Barrier: A Potential New Treatment Modality

In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safely in 5 persons with mild-…

Read the full story

Tuesday, July 03, 2018

Rimegepant Provides Freedom From Pain and Other Symptoms in Phase 3 Clinical Trials

Expanded data from 2 randomized, pivotal phase 3 clinical trials of rimegepant (Biohaven, New Haven, CT), a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist was presented that…

Read the full story

Saturday, June 30, 2018

Addressing the High Impact of Migraine at Work

Initial findings from a large global migraine patient survey involving >11,000 people from 31 countries show migraine is associated with overall work and activity impairment.  The My Migraine …

Read the full story

Friday, June 15, 2018

Ketamine Guidelines for Acute Pain Management Established and Released for the First Time

Intravenous (IV) ketamine has been used to treat acute pain in multiple conditions including as a stand-alone treatment, and as an adjunct to opioids. Ketamine is being used in both inpatient and outp…

Read the full story

Wednesday, June 13, 2018

Atogepant Demonstrates Efficacy and Safety for Prevention of Episodic Migraine

In a phase 2b/3 clinical trial (CGP-MD-01) of the orally administered calcitonin gene-related peptide receptor (CGRP) antagonist, atogepant (Allergan, Ireland), all primary endpoints for all doses and…

Read the full story

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Wednesday, May 23, 2018

New Type of Vertigo Defined That May Be Treatable

Neurologists have defined a new type of vertigo with no known cause (Neurology. 2018:published online May 23). The authors have differentiated this type of vertigo from serious causes of vertigo (eg, …

Read the full story

Wednesday, May 23, 2018

Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Pain

Topline results the first pivotal phase 3 clinical trial of intravenous (IV) tramadol (Avenue Therapeutics, New York, NY) have been released. Enrolled patients were randomized into 1 of 3 regimens: 50…

Read the full story
Load More